Prevalence and Determinants of Agonistic Autoantibodies Against α1-Adrenergic Receptors in Patients Screened Positive for Dementia: Results from the Population-Based DelpHi-Study

Journal of Alzheimer's Disease : JAD
Jochen René ThyrianWolfgang Hoffmann

Abstract

There is a need to assess promising biomarkers for diagnosis and treatment response in real-life settings. Despite the important role of vascular risk factors, cardiovascular biomarkers have played a minor role in dementia research. Agonistic autoantibodies (agAAB) directed against G-protein-coupled receptors (GPCR) are discussed as modulators of pathology and clinical manifestation. 1) Describe prevalence of agAAB directed against GPCR, especially agABB against α1-adrenergic receptors (α1-AR-agAAB) and agABB directed against β2-adrenergic receptors (β2-AR-agAAB) and 2) identify factors associated with agAAB in people with dementia during routine care. Blood samples and data from 95 subjects who screened positive for dementia from a primary care cohort, analyzed using an enzyme-linked immunosorbent assay (ELISA) for detecting agAAB. Sociodemographic and clinical data were assessed, and medical records checked. In 40 (42%) samples, agAAB was detected, with n = 29 (31%) representing α1-AR-agAAB and n = 21 (22%) β2-AR-agAAB. There was no association between the presence of any antibody and a formal diagnosis of dementia. However, patients with coronary heart disease were more likely (OR = 4.23) to have α1-AR-agAAB than those witho...Continue Reading

References

Jun 8, 2001·Zeitschrift für Gerontologie und Geriatrie·H Bickel
Apr 6, 2002·Stroke; a Journal of Cerebral Circulation·J C de la Torre
Jan 12, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Martin PrinceCleusa P Ferri
Jan 30, 2013·Atherosclerosis. Supplements·Michael DandelRoland Hetzer
Feb 28, 2013·Central European Journal of Public Health·Jochen René Thyrian, Wolfgang Hoffmann
Jan 15, 2014·Biochemical Pharmacology·Bushra ImtiazHilkka Soininen
Jun 6, 2014·Journal of Alzheimer's Disease : JAD·Tilly EichlerWolfgang Hoffmann
Nov 12, 2014·BMC Medicine·Johannes Attems, Kurt A Jellinger
Sep 1, 2015·Lancet Neurology·Stefan TeipelAndreas Fellgiebel
Oct 19, 2016·Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy·Petra HempelMarion Bimmler
Mar 1, 2015·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Tilly EichlerWolfgang Hoffmann
Aug 5, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·UNKNOWN METACOHORTS Consortium. Electronic address: joanna.wardlaw@ed.ac.uk, UNKNOWN METACOHORTS Consortium
Apr 14, 2017·Zeitschrift für Gerontologie und Geriatrie·Ingo KilimannStefan J Teipel
Jul 27, 2017·JAMA Psychiatry·Jochen René ThyrianWolfgang Hoffmann

❮ Previous
Next ❯

Citations

Sep 25, 2019·Journal of the American Heart Association·Amanda J Miller, Taylor A Doherty
Oct 30, 2020·Frontiers in Pharmacology·Dianne M Perez
Jun 12, 2021·Frontiers in Cell and Developmental Biology·Dianne M Perez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Related Papers

Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
Petra HempelMarion Bimmler
© 2022 Meta ULC. All rights reserved